Investor Alert: Robbins LLP Informs Investors of the Altimmune, Inc. Class Action Lawsuit

Core Viewpoint - A class action lawsuit has been filed against Altimmune, Inc. for allegedly misleading investors regarding the results of its IMPACT Phase 2b MASH trial, leading to a significant drop in stock price [2]. Group 1: Company Overview - Altimmune, Inc. is a clinical stage biopharmaceutical company focused on developing treatments for obesity, metabolic, and liver diseases [1]. Group 2: Allegations and Impact - The lawsuit claims that during the class period, Altimmune's management made positive statements about the expected results of the MASH trial [2]. - On June 26, 2025, Altimmune announced that it failed to achieve statistical significance in the trial due to a higher-than-expected placebo response, resulting in a stock price drop from $7.71 to $3.61, a decline of over 53% in one day [2]. Group 3: Legal Proceedings - Shareholders interested in serving as lead plaintiffs must submit their papers by October 6, 2025, and can choose to remain absent class members if they do not wish to participate [3].